XTRA:SRT3Life Sciences
Is Sartorius (XTRA:SRT3) Undervalued After Stem Cell Media Growth News?
A new market research report on stem cell culture media has put Sartorius (XTRA:SRT3) in focus, highlighting the company as a key participant as pharmaceutical and biotechnology groups expand their use of stem cell technologies.
See our latest analysis for Sartorius.
Sartorius shares, which last closed at €219.4, have had a mixed run, with the 1-year total shareholder return of 2.88% contrasting with weaker multi year figures. This suggests recent momentum is stabilising after earlier...